Project Grant K99HL177310
Award Date 9/5/25
Completion Date 8/31/27
Dollars Obligated $130K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award for $802,301, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research by Weill Medical College of Cornell University to investigate the mechanisms that control the bone marrow "niche" environment and its role in expanding mutated blood stem cells that increase the risk of cardiovascular disease and cancer. The research aims to identify signaling pathways that can be targeted to prevent...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $787,267 to Yale University from January 1, 2025 to November 30, 2028 to conduct research aimed at determining whether genetic deletion of the DHCR24 enzyme in macrophages or hepatocytes can attenuate the progression of atherosclerosis. The project will exploit novel animal models and cutting-edge genomic and metabolomic technologies to evaluate the therapeutic...
- The federal Project Grant award titled "REDUCING PLASMA CHOLESTEROL AND ATHEROSCLEROSIS USING MICRORNA-30C ANALOG C2" was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to New York University's Long Island School of Medicine. The $1,364,153 award, granted on September 24, 2025, supports research to investigate the use of a synthetic microRNA-30c analog, C2, to reduce plasma cholesterol levels and atherosclerosis in mice. The...
- This $548,816 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Illinois to investigate the role of the SEC16B protein in regulating lipid metabolism and transport in the liver. The project aims to define how SEC16B mediates the formation of lipid droplets and very low-density lipoprotein (VLDL) secretion, which are key processes involved in cholesterol and triglyceride homeostasis. This...
- The University of Texas Southwestern Medical Center received a $772,275 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on how endothelial cell scavenger receptor class B type I (SR-BI) is regulated and interacts with other proteins to drive LDL transcytosis and promote atherosclerosis. The award, effective August 25, 2025 through May 31, 2029, aims to determine the mechanisms by which hypercholesterolemia and...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $708,265 in funding to Weill Medical College of Cornell University from September 1, 2025 through June 30, 2029. The research project aims to expand understanding of how fibroblast growth factor homologous factors (FHFs) influence cardiac physiology and how genetic variants contribute to arrhythmias, providing a platform for targeted therapies. Key research objectives...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $1,127,798 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). This 7-year grant, effective February 1, 2025, will support research to understand the role of macrophages in preserving cardiovascular health, illuminating their contributions to cardiovascular disease, and...